LYL 132
Alternative Names: GSK-4427296; LYL-132Latest Information Update: 28 Jan 2024
At a glance
- Originator Lyell Immunopharma
- Developer GSK; Lyell Immunopharma
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liposarcoma; Synovial sarcoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Liposarcoma(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Liposarcoma(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Canada (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Liposarcoma(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Germany (IV, Infusion)